Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine : A Post Hoc Analysis
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron)
Samaan, Karen H. (Eli Lilly and Company)
Schwedt, Todd J. (Mayo Clinic (Scottsdale, Estats Units d'Amèrica))
Nicholson, Robert A. (Eli Lilly and Company)
Rettiganti, Mallikarjuna (Eli Lilly and Company)
Pearlman, Eric M. (Eli Lilly and Company)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	The consistency of the treatment effect of galcanezumab throughout the dosing interval is examined in patients with episodic and chronic migraine. This study was a post hoc analysis of clinical trial data from episodic (EVOLVE-1; EVOLVE-2; both 6-month duration) and chronic (REGAIN; 3-month duration) migraine double-blind trials evaluating the efficacy of a once-monthly injection of galcanezumab 120 mg relative to placebo. Adults with episodic (placebo, n = 894; galcanezumab, n = 444) or chronic migraine (placebo, n = 558; galcanezumab, n = 278) were included. Mean change from baseline in weekly migraine headache days, averaged across all months for each week of the dosing interval, was compared between groups and within the galcanezumab group during weeks 1 and 4. Additional analyses examined the mean difference from placebo in weekly migraine headache days and a day-by-day analysis. Weekly migraine headache day reduction was significantly greater with galcanezumab relative to placebo every week (P < 0. 001) and did not differ during weeks 1 and 4 for those with episodic (P = 0. 740) or chronic migraine (P = 0. 231) taking galcanezumab. Estimated probabilities of migraine on day 2 and day 30 did not differ for those with episodic (P = 0. 61) or chronic migraine (P = 0. 616) taking galcanezumab. This analysis demonstrates once monthly galcanezumab exhibits consistent efficacy throughout the dosing interval among the population of patients with migraine in three clinical trials evaluating the efficacy of galcanezumab. There is no evidence from these trials that the effect of galcanezumab "wears off" at the end of the dosing interval. ClinicalTrials. gov identifier: EVOLVE-1 (NCT02614183); EVOLVE-2 (NCT02614196); REGAIN (NCT02614261).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Chronic ; Efficacy ; Episodic ; Galcanezumab ; Migraine ; Wear off
Publicat a:	Advances in Therapy, Vol. 38 (may 2021) , p. 3154-3165, ISSN 1865-8652

DOI: 10.1007/s12325-021-01708-8
PMID: 33950375

12 p, 764.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats